- Home
- TYGO vs NVCT Comparison
TYGO vs NVCT Comparison
Compare TYGO & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYGO | NVCT |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 193.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | TYGO | NVCT |
|---|---|---|
| Price | $3.38 | $8.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $15.33 |
| AVG Volume (30 Days) | ★ 1.0M | 70.7K |
| Earning Date | 02-10-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,781,000.00 | N/A |
| Revenue This Year | $95.54 | N/A |
| Revenue Next Year | $21.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 97.41 | N/A |
| 52 Week Low | $0.58 | $5.55 |
| 52 Week High | $4.50 | $11.52 |
Technical Indicators
Market Signals| Indicator | TYGO | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 84.15 | 60.14 |
| Support Level | $3.11 | $8.08 |
| Resistance Level | $3.80 | $8.93 |
| Average True Range (ATR) | 0.29 | 0.49 |
| MACD | 0.23 | -0.03 |
| Stochastic Oscillator | 85.96 | 49.16 |
Price Performance
Historical ComparisonAbout TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.